In the future, we will strive to break through these limitations and systematically analyze the mediating mechanism of gut microbiota metabolites in CEA release through metabolomics combined with transcriptomics so as to reveal the causal network of the microbiota-metabolism-immunity axis that drives cancer progression. The gene discussed is CEACAM5; the disease is cancer.